Please login to the form below

Not currently logged in
Email:
Password:

PRV

This page shows the latest PRV news and features for those working in and with pharma, biotech and healthcare.

Alexion uses priority review voucher for Soliris follow-up

Alexion uses priority review voucher for Soliris follow-up

priority review voucher (PRV) to accelerate the FDA’s review. ... Alexion is sitting on a pair of PRVs awarded for earlier approvals for rare disease therapies (Strensiq and Kanuma), and it’s a measure of the importance the company attaches to

Latest news

  • Sanofi pays $245m for FDA priority review voucher Sanofi pays $245m for FDA priority review voucher

    PRV reduces review time from ten to six months. Sanofi has bought another voucher that slices four months off the FDA review process, b ut hasn't yet said how it ... The French pharma major is paying small US drugmaker Retrophin $245m for the priority

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Licence. 145. Sarepta Therapeutics/  Gilead Sciences. PRV received when EXONDYS 51 was FDA approved for Duchenne muscular dystrophy. ... Sale of Priority Review Voucher (PRV). 125. Cytokinetics/ Royalty Pharma. 4.5% royalty on global sales of omecamtiv

  • Pharma deals in August 2015 Pharma deals in August 2015

    In 2012 the PRV programme was extended to include rare pediatric diseases and the emergence of trading in PRVs was noted in our last annual Deal Watch report. ... Keeping this trend, United Therapeutics has sold a PRV to AbbVie for a headline value of

  • Pharma deals in May 2015 Pharma deals in May 2015

    The paediatric PRV was issued when Cholbam was approved for the treatment of patients with peroxismal disorders. ... 300. Retrophin/ Sanofi. Acquisition of priority review voucher [PRV]. For Cholbam [cholic acid] in bile acid disorders.

  • Pharma deals during November 2014 Pharma deals during November 2014

    BioMarin was awarded a Rare Pediatric Disease PRV when it received approval of Vimizim, a new biological product for patients with Mucopolysaccharidosis type IVA. ... Selling PRVs is a relatively new area and so these two deals provide initial benchmarks,

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...

Infographics